by Sucralfate is a drug used to protect the lining of the stomach and duodenum from further acid damage. It is primarily used to treat ulcers (sores) in the digestive tract. Sucralfate forms a protective coating and shields the stomach and intestine mucosa from further damage by stomach acid and pepsin. It also promotes the healing of existing ulcers by binding to ulcers and protecting damaged areas from further irritation. The drug is available in tablet and suspension forms and is primarily administered orally. Sucralfate is an effective treatment for ulcers caused by nonsteroidal anti-inflammatory drugs (NSAIDs) and stress. Its protective coating property makes it beneficial for the healing of stomach and duodenal ulcers.
The global U.S. Sucralfate Market is estimated to be valued at US$ 60.8 Mn in 2023 and is expected to exhibit a CAGR of 4.2% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the key trends in the U.S. Sucralfate market is the emergence of generic drugs. With key patents of branded sucralfate drugs set to expire in the coming years, the market is expected to witness the entry of numerous generic variants. This is anticipated to make treatment more affordable and accessible to a larger patient base. Generic drugs are typically priced 30-80% lesser than their branded counterparts. Increased uptake of low-cost generics is projected to drive the overall volume growth of the market during the forecast period. Moreover, growing prevalence of gastrointestinal ulcers and rising adoption of OTC sucralfate drugs are also expected to propel the market expansion. However, strict regulatory guidelines may slightly impact market growth. Nonetheless, increasing awareness and availability of sucralfate for gastroprotection are likely to open new avenues for the U.S. Sucralfate market.
Porter’s Analysis
Threat of new entrants: The threat of new entrants is moderate as there are stringent regulations for new drug approvals in the pharmaceutical industry. However, generic manufacturers face lower entry barriers.
Bargaining power of buyers: The bargaining power of buyers is moderate to high as large pharmaceutical buyers can negotiate discounts and influence drug prices. Generic competition also affects buyer power.
Bargaining power of suppliers: The bargaining power of suppliers is low to moderate as there are many raw material suppliers for sucralfate. However, suppliers may wield some power for niche or proprietary ingredients.
Threat of new substitutes: The threat of new substitutes is moderate as new drug delivery mechanisms or alternative treatment options can emerge over time. However, sucralfate’s unique mechanism of action provides some protection.
Competitive rivalry: Competition in the U.S. sucralfate market is expected to remain high between branded and generic players.
Key Takeaways
The global U.S. Sucralfate Market Size is expected to witness high growth, exhibiting CAGR of 4.2% over the forecast period 2023 to 2030, due to increasing prevalence of gastric ulcers in the country. The market size for 2023 is estimated to be US$ 60.8 Mn.
The western region currently dominates the U.S. sucralfate market due to high adoption of branded drugs in this region. However, the southern region is expected to witness fastest growth during the forecast period owing to growing generic drug sales through large retail pharmacy chains in this region.
Key players operating in the U.S. sucralfate market are Sanofi, Teva Pharmaceutical Industries, Taro Pharmaceuticals, Mylan N.V., and Perrigo Company PLC. Sanofi holds the leading market share with its branded drug Carafate. However, Teva and Taro have a sizable share of the generic sucralfate market in the country.
